A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection (OSAKA)
A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)
Sponsor: Astellas Pharma Inc
Listed as NCT00717470, this PHASE4 trial focuses on Kidney Transplantation and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Albacete, Spain , Alicante, Spain , Ancona, Italy , Angers, France , Athens, Greece , Banska Bysterica, Slovakia , Barakaldo-Vizcaya, Spain , Barcelona, Spain and 92 more locations